The overall objective of the present study was to determine the potential clinical usefulness of aspirin and naproxen for PCa prevention employing preclinical models of TMPRSS2-ERG fusion- and Pten loss-driven (given that Pten loss together with the TMPRSS2-ERG fusion initiate neoplastic events) [10] as well as non-TMPRSS2-ERG-driven PCa tumorigenesis. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.